Autologous stem cell transplantation in lymphoma

被引：27

作者：

Schmitz, Norbert ^{[1
]}

Buske, Christian ^{[1
]}

Gisselbrecht, Christian ^{[1
]}

机构：

[1] ASKLEPIOS Klin St Georg, Dept Hematol & Stem Cell Transplantat, D-20099 Hamburg, Germany

来源：

SEMINARS IN HEMATOLOGY | 2007年 / 44卷 / 04期

关键词：

D O I：

10.1053/j.seminhematol.2007.08.007

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

High-dose therapy (HDT) followed by autologous transplantation of hematopoietic stem cells (ASCT) is frequently performed in patients with lymphoma. For many subentities, reliable results from prospective randomized studies are missing. In Hodgkin's disease (HD), HDT/ASCT is a standard indication for patients with chemosensitive first relapse. Patients with indolent or aggressive B-cell lymphoma may benefit from HDT/ASCT if considered as part of first-line therapy or at the time of relapse. However, new randomized studies comparing HDT/ASCT with optimal chemoimmunotherapy are necessary because the introduction of monoclonal antibodies (rituximab) significantly improved the results of conventional chemotherapy. Because data on patients with less frequent entities like mantle cell lymphoma, T-cell lymphoma, Burkitt's lymphoma, or lymphoblastic lymphoma are insufficient, the role of HDT/ASCT needs further study. © 2007 Elsevier Inc. All rights reserved.

引用

页码：234 / 245

页数：12

共 83 条

[61] AUTOLOGOUS BONE-MARROW TRANSPLANTATION AS COMPARED WITH SALVAGE CHEMOTHERAPY IN RELAPSES OF CHEMOTHERAPY-SENSITIVE NON-HODGKINS-LYMPHOMA [J].

PHILIP, T ;

GUGLIELMI, C ;

HAGENBEEK, A ;

SOMERS, R ;

VANDERLELIE, H ;

BRON, D ;

SONNEVELD, P ;

GISSELBRECHT, C ;

CAHN, JY ;

HAROUSSEAU, JL ;

COIFFIER, B ;

BIRON, P ;

MANDELLI, F ;

CHAUVIN, F .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (23) :1540-1545

[62]

Press OW, 2000, BLOOD, V96, P2934

[63]

PROCTOR SJ, 1991, EUR J CANCER, V27, P624, DOI 10.1016/0277-5379(91)90231-2

[64] ChIVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease [J].

Radford, JA ;

Rohatiner, AZS ;

Ryder, WDJ ;

Deakin, DP ;

Barbui, T ;

Lucie, NP ;

Rossi, A ;

Dunlop, DJ ;

Cowan, RA ;

Wilkinson, PM ;

Gupta, RK ;

James, RD ;

Shamash, J ;

Chang, J ;

Crowther, D ;

Lister, TA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (13) :2988-2994

[65]

ROBINSON SP, UNPUB BLOOD

[66]

RODRIGUEZ MA, 2003, BLOOD, V102, P11

[67] VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: Results of a prospective randomized trial by the non-Hodgkin's lymphoma cooperative study group [J].

Santini, G ;

Salvagno, L ;

Leoni, P ;

Chisesi, T ;

De Souza, C ;

Sertoli, MR ;

Rubagotti, A ;

Congiu, AM ;

Centurioni, R ;

Olivieri, A ;

Tedeschi, L ;

Vespignani, M ;

Nati, S ;

Soracco, M ;

Porcellini, A ;

Contu, A ;

Guarnaccia, C ;

Pescosta, N ;

Majolino, I ;

Spriano, M ;

Vimercati, R ;

Rossi, E ;

Zambaldi, G ;

Mangoni, L ;

Endrizzi, L ;

Sileni, VC ;

Miggiano, MC ;

Marino, G ;

Damasio, E ;

Rizzoli, V .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) :2796-2802

[68] Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease:: a randomised trial [J].

Schmitz, N ;

Pfistner, B ;

Sextro, M ;

Sieber, M ;

Carella, AM ;

Haenel, M ;

Boissevain, F ;

Zschaber, R ;

Müller, P ;

Kirchner, H ;

Lohri, A ;

Decker, S ;

Koch, B ;

Hasenclever, D ;

Goldstone, AH ;

Diehl, V .

LANCET, 2002, 359 (9323) :2065-2071

[69]

Schmitz N, 2005, J CLIN ONCOL, V23, p562S

[70] High-dose, therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: Results from the randomized European CUP trial [J].

Schouten, HC ;

Qian, W ;

Kvaloy, S ;

Porcellini, A ;

Hagberg, H ;

Johnsen, HE ;

Doorduijn, JK ;

Sydes, MR ;

Kvalheim, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (21) :3918-3927

← 1 2 3 4 5 6 7 8 9 →